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13% of cases (3%–5% without associated Cyclin D1 loss of BRCA genes in familial cases. The mechanistic
amplification). In sporadic ovarian cancer, increased implications of the BRCA2-EMSY interactions remain to
EMSY gene copy numbers were observed in 17% of 360 be fully defined, and demonstration that EMSY over-
cases (10% independent of Cyclin D1 amplification). In a expression is sufficient to drive tumorigenesis will be
panel of tumors representing diverse histologies, EMSY essential before we can conclude that it encodes a
gene amplification was present in 1/5 hepatocellular proto-oncogene involved in the maintenance of geno-
cancers and in 1/7 melanomas. mic integrity. However, the combination of elegant bio-
Taken all together, these observations suggest that chemical and genetic analyses of this novel BRCA2-
EMSY overexpression through amplification may con- associated protein provides important new insight into
tribute to tumorigenesis in a subset of sporadic cancers. a pathway that is disrupted in human breast and ovar-
Whether EMSY overexpression is sufficient to drive tu- ian cancers.
morigenesis is difficult to ascertain solely on the basis
of such genetic studies, and will require demonstration Daniel A. Haber
of oncogenic effects in experimental systems. Cell-based Massachusetts General Hospital Cancer Center
transformation assays are not easily adaptable to mea- Harvard Medical School
suring the effects of genes that regulate genomic stabil- Charlestown, Massachusetts 02129
ity, whose effects on cellular proliferation may be indi-
rect. However, mice with attenuated BRCA2 develop Selected Reading
lymphoid tumors (Patel et al., 1998), and tissue-specific
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man, S., Wahrer, D.C., Sgroi, D.C., Lane, W.S., Haber, D.A., andtumors, indicating that this pathway can successfully be
Livingston, D.M. (2001). Cell 105, 149–160.modeled in the mouse. The development of transgenic
Hughes-Davies, L., Huntsman, D., Ruas, M., Fuks, F., Bye, J., Chin,mice with mouse mammary tumor virus (MMTV)-driven
S.-F., Milner, J., Brown, L.A., Hsu, R., Gilks, B., et al. (2003). Cellexpression of Cyclin D1 was critical in demonstrating
115, this issue, 523–535.
that Cyclin D1 is a specific target of gene amplification
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ments will be required to confirm the role of EMSY in tu-
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morigenesis.
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A provocative observation from these clinical studies Evans, M.J., Colledge, W.H., Friedman, L.S., Ponder, B.A., and Ven-
is that EMSY amplification is associated with an adverse kitaraman, A.R. (1998). Mol. Cell 1, 347–357.
prognosis, a median disease-free survival of 6.4 years Schuuring, E. (1995). Gene 159, 83–96.
in breast cancer cases with gene amplification, versus Sharan, S.K., Morimatsu, M., Albrecht, U., Llim, D., Regel, E., Dinh,
14 years in cases with diploid gene copy numbers (p  C., Sands, A., Eichele, G., Hasty, P., and Bradley, A. (1997). Nature
0.002). This difference was most prominent in cases 386, 804–810.
without evidence of metastases to regional lymph nodes Thai, Th., Du, F., Tsan, J.T., Jin, Y., Phung, A., Spillman, M.A., Massa,
H.F., Mul, C.Y., Ashfaq, R., Mathis, J.M., et al. (1998). Hum. Mol.at the time of diagnosis, and it was not evident in those
Genet. 7, 195–202.with positive lymph nodes (possibly reflecting the pres-
Venkitaraman, A.R. (2002). Cell 108, 171–182.ence of other genetic lesions). Previous studies of 11q13
Wang, T.C., Cardiff, R.D., Zukerberg, L., Lees, E., Arnold, A., andamplification in breast cancer have also suggested a
Schmidt, E.V. (1994). Nature 369, 669–671.correlation with disease recurrence (reviewed in Schuur-
ing 1995), and while the current analysis did not exclude
cases with concomitant amplification of Cyclin D1 or
EMSI, multivariate analysis indicated that the link be-
tween prognosis and gene amplification reached statis- Rad53: A Controller Ensuringtical significance for EMSY, but not for Cyclin D1. These
observations are unlikely to have immediate clinical im- the Fine-Tuning of Histone Levels
pact, since other features currently used in clinical prac-
tice, such as tumor size, were more informative than
EMSY amplification status, and other important charac-
Checkpoint proteins are activated in response to ge-teristics, such as tumor histology and grade were not
notoxic insults or replication stress to maintain ge-studied. However, comparing the clinical and molecular
nome integrity. Their function is believed to dependfeatures of breast cancers with EMSY amplification with
largely on the detection of the DNA damage or defectsthose resulting from inactivation of BRCA1 or BRCA2
occurring during replication fork progression.may prove to be very interesting. While BRCA2 null
breast cancers do not appear to have distinct histopath-
In this issue of Cell, Gunjan and Verreault (2003) revealological or clinical characteristics, those associated with
a novel function for the S. cerevisiae checkpoint kinaseinactivation of BRCA1 are more commonly poorly differ-
Rad53 as a participant in a surveillance mechanism thatentiated, estrogen-receptor negative, and exhibit some
prevents the accumulation of nonnucleosomal histonescharacteristic histopathological features (reviewed in
in the cell.Osin and Lakhani, 1999).
It is widely accepted that, upon DNA damage andIn sum, the studies of Hughes-Davies and coworkers
replication stress, checkpoint responses arrest the cellwill generate considerable interest by their suggestion
cycle to provide additional time for repair and thus con-that overexpression of EMSY in some sporadic breast
and ovarian cancers may be functionally equivalent to tribute to genome integrity (Zhou and Elledge, 2000). In
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Figure 1. Rad53 and the Maintenance of His-
tone Levels
In this simplified model, newly synthesized
histones, after their association with chaper-
ones (step 1), provide a pool of histones avail-
able for deposition onto DNA (step 2). The
available histones can interact dynamically
with Rad53 (step3), which can promote his-
tone degradation (step 4). In this way, a tightly
regulated level of nonnucleosomal histones
is maintained.
S. cerevisiae, the Mec1 and Rad53 checkpoint kinases histone overexpression. This result suggests that his-
tone overexpression does not simply activate the known(orthologs of ATM/ATR and Chk2 in mammals) play cru-
checkpoint function of Rad53, but requires an indepen-cial roles in the DNA damage response during S phase
dent function of Rad53 in histone degradation. A critical(Tercero et al., 2003). So far, most of the known functions
issue was thus to understand how Rad53 could senseof Rad53 are dependent upon its activation by the up-
histone levels. A link between histone metabolism andstream kinase Mec1. However, the observation that
Rad53 was previously established through the interac-Rad53 deletion mutants displayed a slow growth pheno-
tion of Rad53 and Asf1 (Emili et al., 2001; Hu et al.,type that is absent in the Mec1 deletion mutants during
2001). Interestingly, this interaction is not involved in thean unperturbed cell cycle (Zhao et al., 2001) indicated
Rad53-dependent histone downregulation. A significantthe existence of a Mec1-independent function for Rad53
proportion of Rad53 copurifies with histones indepen-during cell cycle, which until now had remained elusive.
dently of the known histone chaperones Asf1, CAC-1,In S. cerevisiae and most somatic cells in vertebrates,
CAC-2, and Hir1/2, suggesting either that Rad53 bindshistone synthesis is coordinated with DNA replication
histones directly or that it uses an as-yet-unidentifiedduring S phase in order to provide a supply of histones
chaperone intermediate. Since a version of Rad53 mu-at a time when the newly replicated DNA is assembled
tated in its kinase domain associates more strongly withinto chromatin (Osley, 1991). The rapid histone deposi-
histones, the kinase activity may regulate the Rad53-tion coupled to DNA synthesis is mediated by a histone
histone interaction. A final line of support for a role ofchaperone known as the CAF-1 complex (composed of
Rad53 in regulating histone levels was the observationthree subunits, CAC-1, CAC-2, and CAC-3) (Kaufman et
that Rad53-specific mutant phenotypes such as sensi-al., 1997). Besides such replication-coupled nucleo-
tivity to DNA damage and chromosome loss phenotypessome assembly, alternative pathways operate which in-
found in Rad53 deletion strains are partially rescued byvolve either the histone regulator proteins (Hir1, Hir2,
a reduction in the histone H3-H4 gene dosage.Hir3, and HPC2) (Krawitz et al., 2002) or the histone
The findings by Gunjan and Verreault provide newchaperone Asf1, which in concert with CAF-1 and Hir
insights into a Rad53 surveillance mechanism which canproteins can stimulate nucleosome formation (Tyler et
monitor and regulate histone levels to prevent their toxic
al., 1999 ; Sharp et al., 2001).
effects. In a simple model, histone metabolism would
Since elevated levels of histones and delays between
lead to a distribution of histones into three major pools:
DNA synthesis and histone deposition lead to multiple newly synthesized histones, available histones, or de-
cellular defects, a delicate balance between histone posited histones (Figure 1). During DNA replication, his-
pools and histone demands during DNA replication for tone deposition will consume the pool of available his-
nucleosome assembly must be ensured. It is possible tones, thus decreasing the level of this pool (step 2). A
that, in addition to the transcriptional control of the his- dynamic interaction of Rad53 with available histones
tone genes during S phase, some posttranscriptional could allow Rad53 to promote histone degradation to
mechanisms exist that fine-tune histone levels once the ensure a steady state of available histones (steps 3 and
supply of histones is constituted. 4). In a normal situation, this pathway will ensure the
Gunjan and Verreault now demonstrate that Rad53, maintenance of a regular flow of histones from their
but surprisingly not Mec1 or Tel1, is required for the synthesis to their delivery site. Obviously, an arrest or
downregulation of surplus histones. Cells lacking Rad53 delay in DNA synthesis, which would prevent histone
are hypersensitive to histone overexpression and fail to use for deposition (step 2), would increase the pool of
degrade excess histones. Taken together, these data histones available. In such cases, degradation of the
establish that Rad53 exerts a control on histone stability. excess histones available (steps 3 and 4) would be es-
Interestingly, both survival to histone overexpression sential to minimize their accumulation and subsequent
and the ability to degrade histone require the intact cytotoxic effects. Importantly, since this mechanism
kinase domain of Rad53 and are independent of Mec1. acts independently of upstream kinases, it can provide
Furthermore, Rad53 phosphorylation, a marker for DNA Rad53 with the ability to respond very rapidly to his-
tone accumulation.checkpoint activation, could not be detected following
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Tercero, J.A., Longhese, M.P., and Diffley, J.F.X. (2003). Mol. CellA key issue that remains to be addressed concerns
11, 1323–1326.the regulation of the mechanism involved in sensing
Tyler, J.K., Adams, C.R., Chen, S.R., Kobayashi, R., Kamakaka, R.T.,the histone levels (step 3). How the different histone-
and Kadonaga, J.T. (1999). Nature 402, 555–560.interacting partners contribute to this sensing has not
Zhao, X., Chabes, A., Domkin, V., Thelander, L., and Rothstein, R.yet been established. It is intriguing that only exoge-
(2001). EMBO J. 20, 3544–3553.
nously provided CAC-1, but not Hir1/2, allows survival
Zhou, B.B., and Elledge, S.J. (2000). Nature 408, 433–439.of a rad53 mutant in the presence of excessive histones.
The nature of the interaction (affinity, stability) between
histones and their chaperones may be important in
“buffering” the pool of histones. It will be important to
examine how histones may be redistributed among their
different partners (chaperones), including Rad53, to Brain or Brawn:
allow the degradation only of histones in excess. How FGF Signaling Gives Us Both
These interactions could provide a possible means of
interfering with the stability of a Rad53-histone complex.
How the histones are actually degraded (step 4) and
how Rad53 provides the connection to a specific degra- How does FGF (fibroblast growth factor) signaling in-
dation pathway will also need to be determined. Histone duce both neural and mesodermal cell fates in the
degradation may be prevented by interaction with spe- early embryo? Two papers address this fundamental
cific chaperones. This could be particularly critical, in the question in this issue of Cell. Bertrand et al. show in
context of early development in Xenopus or Drosophila the ascidian that a GATA factor determines the neural
embryos, when maternal pools of histones are accumu- response of animal cells to FGF signaling, while in the
lated to fulfill the demands of rapid cell divisions during chick, Sheng et al. demonstrate that the slow induction
embryonic cell cycles. by FGF of a new transcription factor (Churchill) in the
This work has made use of S. cerevisae as a powerful neural plate in turn induces expression of Sip1 (Smad
model system to reveal an exciting new role for Rad53 in interacting protein-1), which inhibits mesodermal
a mechanism that ensures the maintenance of a steady genes and sensitizes cells to later neural inducing
state pool of histones. This function contributes to nor- factors.
mal cell growth and survival in the face of both DNA
damage and replication stress independently of the con- Following Spemann and Mangold’s initial observation
ventional checkpoint pathways. of neural induction by organizer-derived signals in the
Rad53 function is conserved among eukaryotes, and 1920s, developmental biologists have been in search of
the human homolog Chk2 acts as a tumor suppressor. the molecular basis of this process. A major break-
It will therefore be of major interest to determine if such through came some 10 years ago with the discovery
a mechanism is conserved and how it may contribute that inhibiting BMP (bone morphogenetic protein) sig-
to the basis of genomic instability found in cancer. naling in amphibian ectoderm promotes neural over epi-
Finally, this work emphasizes the fact that in addition dermal cell fates and that many BMP antagonists are
to sensing defects at the DNA level, checkpoint proteins expressed by the organizer. This led to the proposal
can allow cells to monitor parameters associated with of the “default model” for neural induction, in which
chromatin organization, in this case histone levels, in ectoderm cells form neural tissue unless they experi-
order to maintain genomic integrity. ence BMP signaling (Hemmati Brivanlou and Melton,
1997). This model has now been tested in higher verte-
brates. In particular, the formation of neural tissue inJean-Pierre Quivy and Genevie`ve Almouzni
mice lacking both BMP antagonists Noggin and Chordin
Institut Curie
(Wilson and Edlund, 2001) and misexpression experi-
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ments in the chick strongly suggest that inhibition of
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BMP signaling is not sufficient for neural induction in
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these contexts (Wilson and Edlund, 2001). More re-
France
cently, FGF signaling has emerged as a key conserved
pathway mediating neural induction. It is required to
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initiate this process in the chick (reviewed in Wilson
and Edlund, 2001), in ascidians (Hudson et al., 2003), inEmili, A., Schieltz, D.M., Yates, J.R., and Hartwell, L.H. (2001). Mol.
Cell 7, 13–20. Planaria (Cebria et al., 2002), and in mouse ES cells (Ying
et al., 2003), as well as, controversially, prior to the actionGunjan, A., and Verreault, A. (2003). Cell 115, this issue, 537–602.
of BMP antagonists in the amphibian embryo (WilsonHu, F., Alcasabas, A.A., and Elledge, S.J. (2001). Genes Dev. 15,
and Edlund, 2001). But FGF can also induce mesodermal1061–1066.
tissue in the early embryo, and an outstanding problemKaufman, P.D., Kobayashi, R., and Stillman, B. (1997). Genes Dev.
11, 345–357. is to understand how one signaling pathway can elicit
two such different outcomes. In this issue of Cell, Ber-Krawitz, D.C., Kama, T., and Kaufman, P.D. (2002). Mol. Cell. Biol.
22, 614–625. trand et al. (2003) and Sheng et al. (2003) describe the
transcriptional logic downstream of FGF signaling thatOsley, M.A. (1991). Annu. Rev. Biochem. 60, 827–861.
helps separate these distinct developmental programs.Sharp, J.A., Fouts, E.T., Krawitz, D.C., and Kaufman, P.D. (2001).
Curr. Biol. 11, 463–473. In the ascidian Ciona intestinalis, animal cells form
